Mark Steven Miller, Ph.D.

Mark Steven Miller, Ph.D., serves as the Deputy Chief of the Chemopreventive Agent Development Group (CADRG), Division of Cancer Prevention (DCP), National Cancer Institute (NCI). He also is Director of the PREVENT Cancer Preclinical Drug Development Program (PREVENT) Operations, where he oversees and coordinates all PREVENT Program activities.

Dr. Miller’s responsibilities include planning, implementing, and evaluating toxicological and pharmacological initiatives on the development of chemo/immunopreventive agents; providing research support in managing grant and contract portfolios; conducting and consulting on applied drug development programs and studies; and consulting on scientific and technical issues.

Dr. Miller holds a Ph.D. in pharmacology from Columbia University in New York City. Before joining CADRG in 2014, he completed a 25-year career in academia and most recently was a tenured professor of cancer biology at the Wake Forest School of Medicine. During his career in academia, Dr. Miller’s research focused on the pathogenesis of pulmonary cancers, transplacental carcinogenesis, the molecular mechanisms of cancer and chemoprevention processes, gene/environmental interactions in individual susceptibility to lung cancer, and the effects of chemical and physical carcinogens on gene expression regulation.

During his academic career, he has served as a reviewer for NIH, the Environmental Protection Agency (EPA), and the Department of Defense study sections; the National Toxicology Program; the Department of Health for Pennsylvania, and private foundations. He chaired a panel for IRIS Assessment of Nitrobenzene for EPA. He has served as an officer in the Society of Toxicology, and the Genetic and Environmental Mutagenesis Society. Dr. Miller has published more than 100 articles in peer-reviewed journals.